| pubmed-article:14743544 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:14743544 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:14743544 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:14743544 | lifeskim:mentions | umls-concept:C0473169 | lld:lifeskim |
| pubmed-article:14743544 | lifeskim:mentions | umls-concept:C2239176 | lld:lifeskim |
| pubmed-article:14743544 | lifeskim:mentions | umls-concept:C0023890 | lld:lifeskim |
| pubmed-article:14743544 | lifeskim:mentions | umls-concept:C0969677 | lld:lifeskim |
| pubmed-article:14743544 | lifeskim:mentions | umls-concept:C1708528 | lld:lifeskim |
| pubmed-article:14743544 | lifeskim:mentions | umls-concept:C1524063 | lld:lifeskim |
| pubmed-article:14743544 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:14743544 | pubmed:dateCreated | 2004-1-27 | lld:pubmed |
| pubmed-article:14743544 | pubmed:abstractText | Patients with chronic hepatitis C virus (HCV) infection often develop liver cirrhosis and hepatocellular carcinoma (HCC). The purpose of this study was to test the chemopreventive effect of alpha-tocopherol on hepatocarcinogenesis in patients with liver cirrhosis and a history of HCV infection. Eighty-three patients with liver cirrhosis and with positive history of HCV infection were divided at random into two groups. Forty-four patients were treated with alpha-tocopherol (Vit E group) while the other 39 were followed as controls. The clinical background (gender, age, and laboratory data) was similar in the two groups. Serum levels of alpha-tocopherol, albumin, alanine aminotransferase (ALT), and total cholesterol and platelet count were measured serially over a period of five years. The mean serum concentration of alpha-tocopherol was low in both groups at entry and was significantly higher in the Vit E group than in the control group one month after treatment. Platelet count, serum albumin, ALT, and total cholesterol were not different between the two groups during the five-year period. Cumulative tumor-free survival and cumulative survival rate tended to be higher in the Vit E group than in controls, albeit statistically insignificant. The serum level of alpha-tocopherol was low in patients with liver cirrhosis and positive for HCV. Although the administration of alpha-tocopherol normalized the level one month later, it could neither improve liver function, suppress hepatocarcinogenesis, nor improve cumulative survival. Patients treated with alpha-tocopherol tended to live longer without development of HCC but the difference was not statistically significant. | lld:pubmed |
| pubmed-article:14743544 | pubmed:language | eng | lld:pubmed |
| pubmed-article:14743544 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14743544 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:14743544 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14743544 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14743544 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14743544 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14743544 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14743544 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14743544 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:14743544 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:14743544 | pubmed:issn | 0300-9831 | lld:pubmed |
| pubmed-article:14743544 | pubmed:author | pubmed-author:NöllG NGN | lld:pubmed |
| pubmed-article:14743544 | pubmed:author | pubmed-author:TakahashiHito... | lld:pubmed |
| pubmed-article:14743544 | pubmed:author | pubmed-author:TakagiHitoshi... | lld:pubmed |
| pubmed-article:14743544 | pubmed:author | pubmed-author:KakizakiSator... | lld:pubmed |
| pubmed-article:14743544 | pubmed:author | pubmed-author:HashimotoYosh... | lld:pubmed |
| pubmed-article:14743544 | pubmed:author | pubmed-author:MoriMasatomoM | lld:pubmed |
| pubmed-article:14743544 | pubmed:author | pubmed-author:SoharaNaondoN | lld:pubmed |
| pubmed-article:14743544 | pubmed:author | pubmed-author:TakayamaHisas... | lld:pubmed |
| pubmed-article:14743544 | pubmed:author | pubmed-author:YamadaToshihi... | lld:pubmed |
| pubmed-article:14743544 | pubmed:author | pubmed-author:KanekoMiekoM | lld:pubmed |
| pubmed-article:14743544 | pubmed:author | pubmed-author:ShimojoHirosh... | lld:pubmed |
| pubmed-article:14743544 | pubmed:author | pubmed-author:NagamineTakea... | lld:pubmed |
| pubmed-article:14743544 | pubmed:author | pubmed-author:TsukiokaGengo... | lld:pubmed |
| pubmed-article:14743544 | pubmed:author | pubmed-author:TagoYoukoY | lld:pubmed |
| pubmed-article:14743544 | pubmed:author | pubmed-author:KonakaKazukoK | lld:pubmed |
| pubmed-article:14743544 | pubmed:author | pubmed-author:KabeyaKenshiK | lld:pubmed |
| pubmed-article:14743544 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:14743544 | pubmed:volume | 73 | lld:pubmed |
| pubmed-article:14743544 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:14743544 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:14743544 | pubmed:pagination | 411-5 | lld:pubmed |
| pubmed-article:14743544 | pubmed:dateRevised | 2007-2-21 | lld:pubmed |
| pubmed-article:14743544 | pubmed:meshHeading | pubmed-meshheading:14743544... | lld:pubmed |
| pubmed-article:14743544 | pubmed:meshHeading | pubmed-meshheading:14743544... | lld:pubmed |
| pubmed-article:14743544 | pubmed:meshHeading | pubmed-meshheading:14743544... | lld:pubmed |
| pubmed-article:14743544 | pubmed:meshHeading | pubmed-meshheading:14743544... | lld:pubmed |
| pubmed-article:14743544 | pubmed:meshHeading | pubmed-meshheading:14743544... | lld:pubmed |
| pubmed-article:14743544 | pubmed:meshHeading | pubmed-meshheading:14743544... | lld:pubmed |
| pubmed-article:14743544 | pubmed:meshHeading | pubmed-meshheading:14743544... | lld:pubmed |
| pubmed-article:14743544 | pubmed:meshHeading | pubmed-meshheading:14743544... | lld:pubmed |
| pubmed-article:14743544 | pubmed:meshHeading | pubmed-meshheading:14743544... | lld:pubmed |
| pubmed-article:14743544 | pubmed:meshHeading | pubmed-meshheading:14743544... | lld:pubmed |
| pubmed-article:14743544 | pubmed:meshHeading | pubmed-meshheading:14743544... | lld:pubmed |
| pubmed-article:14743544 | pubmed:meshHeading | pubmed-meshheading:14743544... | lld:pubmed |
| pubmed-article:14743544 | pubmed:meshHeading | pubmed-meshheading:14743544... | lld:pubmed |
| pubmed-article:14743544 | pubmed:meshHeading | pubmed-meshheading:14743544... | lld:pubmed |
| pubmed-article:14743544 | pubmed:meshHeading | pubmed-meshheading:14743544... | lld:pubmed |
| pubmed-article:14743544 | pubmed:meshHeading | pubmed-meshheading:14743544... | lld:pubmed |
| pubmed-article:14743544 | pubmed:meshHeading | pubmed-meshheading:14743544... | lld:pubmed |
| pubmed-article:14743544 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:14743544 | pubmed:articleTitle | Pilot clinical trial of the use of alpha-tocopherol for the prevention of hepatocellular carcinoma in patients with liver cirrhosis. | lld:pubmed |
| pubmed-article:14743544 | pubmed:affiliation | First Department of Internal Medicine, Gunma University Faculty of Medicine, 3-39-15, Showa Machi Maebashi, 371-8511, Japan. htakagi@med.gunma-u.ac.jp | lld:pubmed |
| pubmed-article:14743544 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:14743544 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:14743544 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
